Cargando…
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far
Luminal Androgen Receptor Breast Cancers (LAR BCs) are characterized by a triple negative phenotype and by the expression of Androgen Receptor (AR), coupled with luminal-like genomic features. This unique BC subtype, accounting for about 10% of all triple negative BC, has raised considerable interes...
Autores principales: | Stella, Stefania, Martorana, Federica, Massimino, Michele, Vitale, Silvia Rita, Manzella, Livia, Vigneri, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089148/ https://www.ncbi.nlm.nih.gov/pubmed/37056632 http://dx.doi.org/10.2147/OTT.S379867 |
Ejemplares similares
-
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer
por: Massimino, Michele, et al.
Publicado: (2023) -
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells
por: Stella, Stefania, et al.
Publicado: (2023) -
What we know so far
Publicado: (2021) -
Anabaenopeptins: What We Know So Far
por: Monteiro, Patrick Romano, et al.
Publicado: (2021) -
Autoimmune pancreatitis: What we know so far
por: Masood, Muaaz
Publicado: (2021)